Stifel Financial Corp Boosts Position in Eli Lilly and Company (LLY)

Stifel Financial Corp increased its stake in Eli Lilly and Company (NYSE:LLY) by 2.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 709,703 shares of the company’s stock after buying an additional 17,892 shares during the period. Stifel Financial Corp owned about 0.07% of Eli Lilly and worth $59,657,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Beutel Goodman & Co Ltd. bought a new stake in Eli Lilly and during the first quarter valued at $161,084,000. UBS Asset Management Americas Inc. increased its stake in shares of Eli Lilly and by 22.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 6,406,387 shares of the company’s stock worth $471,190,000 after buying an additional 1,195,661 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Eli Lilly and by 48.9% in the fourth quarter. Teachers Advisors LLC now owns 2,642,094 shares of the company’s stock worth $194,326,000 after buying an additional 868,053 shares in the last quarter. Swiss National Bank increased its stake in shares of Eli Lilly and by 24.2% in the first quarter. Swiss National Bank now owns 4,011,443 shares of the company’s stock worth $337,402,000 after buying an additional 781,800 shares in the last quarter. Finally, Comgest Global Investors S.A.S. increased its stake in shares of Eli Lilly and by 581.6% in the first quarter. Comgest Global Investors S.A.S. now owns 742,900 shares of the company’s stock worth $62,485,000 after buying an additional 633,900 shares in the last quarter. 75.48% of the stock is owned by institutional investors.

Eli Lilly and Company (LLY) opened at 82.31 on Friday. The firm has a market cap of $86.84 billion, a price-to-earnings ratio of 35.62 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The stock’s 50 day moving average is $82.99 and its 200 day moving average is $81.53.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the firm posted $0.86 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.53%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.

A number of equities research analysts recently weighed in on the stock. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Friday. BMO Capital Markets reissued a “sell” rating and set a $73.00 target price on shares of Eli Lilly and in a research note on Friday. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. UBS AG lowered shares of Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research note on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a research note on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $88.27.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00. Following the completion of the transaction, the insider now owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. In the last three months, insiders sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.